All News
Biologic-treated Psoriasis has Less Progression to Psoriatic Arthritis
A single center study demonstrates that biologic treatment of psoriasis (PsO) significantly reduces the likelihood of psoriatic arthritis (PsA) development; suggesting a role for more aggressive treatment of PsO.
No Great Options for Treating VEXAS
MedPage Today
For patients with the auto-inflammatory disease VEXAS, treatment decisions are unfortunately fraught with tradeoffs between effectiveness and risk of adverse effects, a French registry study showed.
Read Article
Small-molecule Drugs to Treat Systemic Lupus Erythematosus
A metanalysis of randomized controlled trials (RCTs) on treatments of systemic lupus erythematosus (SLE), confirm the efficacy of several targeted small-molecule drugs.
Pharmacologic Efficacy in Still's Disease
A systematic review of the effectiveness and safety of pharmacological treatments for adult-onset Still’s disease (AOSD) supports the use of either IL-1 or IL-6 inhibitors.
Forbes on the future of CAR-T cell therapy - A Gamechanger For Autoimmune Diseases. Innovation, costs, more trials and regulatory differences for autoimmune (vs cancer) patietns? https://t.co/6Siv0Y1GDB https://t.co/Mmbh4ER7vf https://t.co/j8bgn8DkLw
Dr. John Cush RheumNow ( View Tweet)
Save the date! We are covering #EULAR24! We'll be sharing recaps, videos, and more. https://t.co/NMWtHB94Pi https://t.co/ok43pnagFg
Links:
Dr. John Cush RheumNow ( View Tweet)
Biologic-treated Psoriasis has Less Progression to Psoriatic Arthritis
A single center study demonstrates that biologic treatment of PsO significantly reduces the likelihood of PsA development; suggesting a role for more aggressive treatment of PsO.
https://t.co/VHk2KEsP8d https://t.co/1r4zVAzrMw
Dr. John Cush RheumNow ( View Tweet)
Ramosetron,a 5-HT3 recept antagonist used for post-op N/V,t has been used for adjunctive pain Rx & IBS. An 80 FM pt DBRCT tested PBO vs Ramosetron (.3 mg/day IV x5d). @d5 had signif better VAS pain (1.18 vs 0.54, p< 0.05), but didnt persist till day 28 https://t.co/0ABduv8Nlq https://t.co/WGlxIhst1o
Dr. John Cush RheumNow ( View Tweet)
Do you have a rheumatology question or case for Dr. Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology.
https://t.co/qvVEUoNYi5 https://t.co/duw6jg5xpp
Dr. John Cush RheumNow ( View Tweet)
Preliminary results of ph IIB ORIGIN trial of placebo vs Atacicept (binds BAFF & APRIL)in 166 pts w/ IgA Nephropathy (Berger’s Dz) Gd-IgA1, hematuria, and UPCR (vs PBO) in the blinded 1st 36 weeks of the trial. https://t.co/tPhCrSaSTC https://t.co/6HqGFtb1IE
Links:
Dr. John Cush RheumNow ( View Tweet)
Available online, open access:
A review of CAR-T call therapy in rheumatic disease by @RyuOhno06
See below diagram of CAR-T therapy mechanism in cancer.
https://t.co/WALWulEDkW https://t.co/k1FD0zHtWu
Links:
Seminars in Arthritis and Rheumatism seminarthrheum ( View Tweet)
Treatment of psoriasis with different classes of biologics reduces the likelihood of peripheral and axial psoriatic arthritis development https://t.co/DFdQy1Rn3D
Peter Nash drpnash ( View Tweet)
Research presented at DDW 2024 demonstrated the superiority of guselkumab over ustekinumab or placebo in 1,021 patients with moderately to severely active Crohn's disease enrolled in the phase III GALAXI 2 and GALAXI 3 trials https://t.co/HdZf24Twsq https://t.co/REeAAskpX5
Dr. John Cush RheumNow ( View Tweet)
FAERS retrospective, safety study of JAKi use in 75K RA pts (52K Tofa; 21K Upa, 2.2K Bari vs bDMARDs) found JAKi had incr risk of VTE (adj ROR=2.11), CVA (ROR=1.25), IHD (1.23), edema(1.22), & tachyarrhythmias (1.15) https://t.co/Bvds4C66Nq https://t.co/Xmu8g35MXR
Links:
Dr. John Cush RheumNow ( View Tweet)
Save the date! We’ll be covering #EULAR24! https://t.co/HGjP2SFyOp
Dr. John Cush RheumNow ( View Tweet)
In animal models, IL-22 may have protective effects against pulm fibrosis. Study of 66 new #RA pts (1/2 w/ ILD) & 14 controls. Serum IL-22 was signif lower in RA-ILD; and was inversely correlated with the severity of RA-ILD https://t.co/Rmr5N2JznH https://t.co/OZ1ZrgGXC3
Links:
Dr. John Cush RheumNow ( View Tweet)
The EMAs CHMP has recommended for approval Two biosimilars, Tofidence (tocilizumab) and Wezenla (ustekinumab) https://t.co/mREclYdeCk https://t.co/zQX00Ys8oH
Dr. John Cush RheumNow ( View Tweet)
French insurance claims study of 12071 #PsA pts on biologics (2015-2021) found total of 367 serious infections (3%; IR 1.7/100PY). SIR risk significantly lower for new users of etanercept (wHR 0.72) & ustekinumab (wHR 0.57) (vs ADA new users https://t.co/CutqoxA05e https://t.co/OUCUbrKnFF
Dr. John Cush RheumNow ( View Tweet)
FDA has approved the adalimumab biosimilar Cyltezo (adalimumab-adbm) for the 2nd time, now as a high-concentration, citrate-free formulation for injection (from Boehringer Ingelheim) https://t.co/micTFhjgqm
Dr. John Cush RheumNow ( View Tweet)
🏆Dr. Georg Schett's pioneering work in CAR-T for #autoimmune disease has landed him among the TIME100 Most Influential People in Health
“Not only are the patients in drug-free remission, but I believe many are cured of their autoimmune disease," he said
https://t.co/Rj7FpkluNg
Links:
Healio Rheumatology HealioRheum ( View Tweet)
